The Globe and Mail reports in its Wednesday, Jan. 28, edition that Canaccord Genuity analyst Kenric Tyghe rates Cronos Group "buy" in new coverage. The Globe's David Leeder writes in the Eye On Equities column that Mr. Tyghe set a share target of $4.25. Analysts on average target the shares at $3.16. Mr. Tyghe believes the Canadian cannabis market is a global benchmark for legal commercialization, with potential for growth through regulatory reform, consolidation and international expansion, despite some challenges. Mr. Tyghe says in a note: "Cronos Group is a global cannabinoid company with a differentiated strategy focused on the building of disruptive intellectual property by advancing cannabis research, technology and product development. While Canada and Israel are the company's two largest markets today, we believe that its recent acquisition of CanAdelaar (the largest adult-use cannabis company in today's medically focused European market) and the expansion of Cronos Growing Company (Cronos GrowCo), supported by the strength of Cronos's balance sheet, represent the leading edge of a transformational change."